A drug to treat advanced prostate cancer should be given to patients on the NHS, a health watchdog has said.
Abirateron, marketed as Zytiga, can extend the lives of late-stage cancer sufferers by more than three months.
The National Institute for Health and Clinical Excellence (Nice) revised its recommendations after fresh information from manufacturer Janssen, and the new draft guidance was welcomed by experts.
More top news
Firefighters across California have been battling major wildfires in what could be the most destructive wildfire season on record.
This summer's fundraising juggernaut, the ALS Ice Bucket challenge, has raised almost £7m in the fight against Motor Neurone Disease.
Winning entries from the Astronomy Photographer of the Year 2014 competition have been unveiled.